

# Eiji Kashiwagi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2119141/publications.pdf>

Version: 2024-02-01

73  
papers

1,065  
citations

394421

19  
h-index

477307

29  
g-index

74  
all docs

74  
docs citations

74  
times ranked

1529  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer. <i>International Journal of Urology</i> , 2022, 29, 26-32.	1.0	5
2	Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors. <i>JMA Journal</i> , 2022, 5, 83-90.	0.8	1
3	Validation of models predicting lymph node involvement probability in patients with prostate cancer. <i>International Journal of Urology</i> , 2022, 29, 428-434.	1.0	6
4	Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. <i>Prostate International</i> , 2022, 10, 7-13.	2.3	4
5	An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer. <i>Cancer Science</i> , 2022, 113, 1731-1738.	3.9	10
6	Impact of nerve sparing in robot-assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence. <i>International Journal of Urology</i> , 2022, 29, 824-829.	1.0	7
7	Gene amplification of YB41 in castration-resistant prostate cancer in association with aberrant androgen receptor expression. <i>Cancer Science</i> , 2021, 112, 323-330.	3.9	7
8	Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 365.e1-365.e7.	1.6	3
9	Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy: a case report. <i>International Cancer Conference Journal</i> , 2021, 10, 96-99.	0.5	1
10	Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer. <i>Cancers</i> , 2021, 13, 975.	3.7	11
11	Prognostic impact of prior local therapy in castration-resistant prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1142-1148.	1.3	6
12	Clinical advantages of robot-assisted partial nephrectomy versus laparoscopic partial nephrectomy in terms of global and split renal functions: A propensity score-matched comparative analysis. <i>International Journal of Urology</i> , 2021, 28, 630-636.	1.0	4
13	Differential Impact of TGFBI Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 697955.	2.8	5
14	Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer. <i>Anticancer Research</i> , 2021, 41, 3885-3889.	1.1	3
15	Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	1.4	5
16	The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 733.e17-733.e24.	1.6	2
17	Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer. <i>Cancer Investigation</i> , 2021, 39, 251-256.	1.3	4
18	Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. <i>Prostate International</i> , 2021, 10, 50-55.	2.3	3

#	ARTICLE	IF	CITATIONS
19	Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer. <i>Andrologia</i> , 2021, 54, e14307.	2.1	3
20	Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer. <i>Anticancer Research</i> , 2021, 41, 5593-5598.	1.1	0
21	Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer. <i>Prostate International</i> , 2020, 8, 22-26.	2.3	8
22	Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide. <i>International Journal of Urology</i> , 2020, 27, 1109-1115.	1.0	3
23	The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 931.e1-931.e7.	1.6	5
24	Effect of Smoking on Oncological Outcome among Prostate Cancer Patients after Radical Prostatectomy with Neoadjuvant Hormonal Therapy. <i>Cancer Investigation</i> , 2020, 38, 559-564.	1.3	2
25	FOXO1 inactivation induces cisplatin resistance in bladder cancer. <i>Cancer Science</i> , 2020, 111, 3397-3400.	3.9	14
26	Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 849.e11-849.e18.	1.6	11
27	High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer. <i>Prostate</i> , 2020, 80, 885-894.	2.3	5
28	Thickness of Perirenal Fat Predicts the Growth Pattern of Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 41-48.	0.4	4
29	FOXO1 as a tumor suppressor inactivated via AR/ER $\beta$ signals in urothelial cells. <i>Endocrine-Related Cancer</i> , 2020, 27, 231-244.	3.1	23
30	Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml. <i>Journal of Urology</i> , 2020, 203, 83-91.	0.4	7
31	Role of glucocorticoid signaling in urothelial tumorigenesis: Inhibition by prednisone presumably through inducing glucocorticoid receptor transrepression. <i>Molecular Carcinogenesis</i> , 2019, 58, 2297-2305.	2.7	9
32	Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e21-813.e26.	1.6	0
33	The Role of Nuclear Receptors in Prostate Cancer. <i>Cells</i> , 2019, 8, 602.	4.1	27
34	Psoas muscle volume is correlated with sexual activity and erectile dysfunction among patients with localised prostate cancer. <i>Andrologia</i> , 2019, 51, e13354.	2.1	2
35	Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 3191-3195.	1.1	6
36	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 4808-4819.	7.0	66

#	ARTICLE	IF	CITATIONS
37	Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy. <i>Prostate</i> , 2019, 79, 1147-1155.	2.3	8
38	The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 933-938.	2.3	6
39	Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e387-e393.	1.9	4
40	Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer. <i>Prostate International</i> , 2019, 7, 166-170.	2.3	6
41	Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 180.e19-180.e24.	1.6	20
42	Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone. <i>Prostate International</i> , 2018, 6, 104-109.	2.3	6
43	The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 734-740.	0.4	16
44	Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression. <i>British Journal of Cancer</i> , 2018, 118, 213-223.	6.4	35
45	The interaction between androgen receptor and semenogelin I: a synthetic LxxLL peptide antagonist inhibits the growth of prostate cancer cells. <i>British Journal of Cancer</i> , 2018, 118, 416-420.	6.4	5
46	Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 635.	2.8	4
47	Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy. <i>Molecular and Clinical Oncology</i> , 2018, 9, 575-581.	1.0	5
48	Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. <i>Cancer Science</i> , 2018, 109, 3224-3234.	3.9	21
49	Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide. <i>Prostate</i> , 2018, 78, 1045-1052.	2.3	15
50	Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer. <i>Andrologia</i> , 2018, 50, e13119.	2.1	4
51	Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 4115-4121.	1.1	4
52	Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. <i>Oncotarget</i> , 2018, 9, 30587-30593.	1.8	18
53	Protein kinase C regulates Twist1 expression via NF- $\kappa$ B in prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 171-180.	3.1	10
54	The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 1443-1450.	1.5	11

#	ARTICLE	IF	CITATIONS
55	Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5 $\alpha$ -Reductase Inhibitor. <i>Journal of Urology</i> , 2017, 197, 308-313.	0.4	53
56	Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer. , 2017, 37, 5631-5637.		2
57	ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion. <i>Oncotarget</i> , 2016, 7, 53599-53610.	1.8	26
58	Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer. <i>Oncotarget</i> , 2016, 7, 49169-49179.	1.8	56
59	Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine. <i>Prostate</i> , 2016, 76, 744-756.	2.3	19
60	Antitumor activity of recombinant Bacille Calmette-GuÃ©rin secreting interleukin-15-Ag85B fusion protein against bladder cancer. <i>International Immunopharmacology</i> , 2016, 35, 327-331.	3.8	15
61	Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract. <i>Cancer Biology and Therapy</i> , 2016, 17, 1188-1196.	3.4	40
62	Equl inhibits prostate cancer growth through degradation of androgen receptor by Sâ€phase kinaseâ€associated protein 2. <i>Cancer Science</i> , 2016, 107, 1022-1028.	3.9	31
63	Enzalutamide inhibits androgen receptorâ€positive bladder cancer cell growth. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 432.e15-432.e23.	1.6	33
64	Cyclosporine A and tacrolimus inhibit urothelial tumorigenesis. <i>Molecular Carcinogenesis</i> , 2016, 55, 161-169.	2.7	27
65	Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. <i>Oncotarget</i> , 2015, 6, 1582-1593.	1.8	52
66	Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression. <i>Molecular Endocrinology</i> , 2015, 29, 1486-1497.	3.7	34
67	ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. <i>Oncotarget</i> , 2015, 6, 29860-29876.	1.8	83
68	Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml. <i>Anticancer Research</i> , 2015, 35, 6137-45.	1.1	5
69	Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer. <i>Anticancer Research</i> , 2015, 35, 6925-32.	1.1	6
70	Loss of GATA3 in bladder cancer promotes cell migration and invasion. <i>Cancer Biology and Therapy</i> , 2014, 15, 428-435.	3.4	46
71	Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 431-441.	3.1	35
72	Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer. <i>Prostate</i> , 2012, 72, 741-751.	2.3	22

#	ARTICLE	IF	CITATIONS
73	Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer. International Journal of Urology, 0, , .	1.0	0